Acyclovir-acres
Active material: Acyclovir
When ATH: D06BB03
CCF: Antivirals for outdoor use
When CSF: 09.02.01
Manufacturer: Chemical-Pharmaceutical Plant JSC QUINACRINE (Russia)
PHARMACEUTICAL FORM, COMPOSITION AND PACKAGING
◊ Ointment for external application 5% white or almost white in color with a characteristic smell.
| 1 g | |
| acyclovir | 50 mg |
Excipients: propylene glycol, vaseline, Oil vaseline, wax emulsion, macrogol (polyethylene oxide 1500), Purified water.
5 g – aluminum tuba (1) – packs cardboard.
Pharmacological action
Antiviral agent. Thymidine kinase virus infected cells actively converts acyclovir through successive reactions in Mono, di- and acyclovir triphosphate. Last interacts with the viral DNA polymerase and incorporated into DNA, which is synthesized for new viruses. Thus, formed “defective” viral DNA, which leads to suppression of new generations of virus replication.
Aciclovir is active against Herpes simplex virus types 1 and 2, вируса Varicella zoster, Epstein-Barr virus and Cytomegalovirus.
Pharmacokinetics
The ingestion bioavailability of 15-30%. Widely distributed in the tissues and liquid body Wednesday. Plasma protein binding is 9-33%. It is metabolized in the liver. T1/2 ingestion – 3.3 no, at / in the introduction – 2.5 no. Excreted in the urine, in minor amounts – with feces.
Testimony
For systemic use (inside and/): infection, caused by Herpes simplex virus types 1 and 2 and Varicella zoster; prevention of infections, caused by the Herpes simplex virus and Varicella zoster (incl. in patients with low immunity); as part of an integrated therapy with the express immunodeficiency (incl. When the clinical picture of HIV infection) and patients, undergoing a bone marrow transplant; Prevention of Cytomegalovirus infection after bone marrow transplantation.
For topical use in ophthalmology: keratitis and other lesions of the eye, caused by the virus Herpes simplex.
For outdoor use: infections of the skin, caused by viruses Herpes simplex and Varicella zoster.
Dosage regimen
Inside adults and children over 2 years – by 200-400 mg 3-5 time / day, if necessary – by 20 mg / kg (to 800 mg per reception) 4 times / day. Children under the age of 2 years used in dose, half the dose for adults. Length of treatment – 5-10 days. When kidney failure recommended correction mode.
B/drip in adults and children older than 12 years – by 5-10 mg / kg, the interval between wvedeniami – 8 no. Children aged 3 Months before 12 years – by 250-500 mg / m2 body surface, the interval between wvedeniami – 8 no. For newborns dose is 10 mg / kg, the interval between wvedeniami – 8 no.
When kidney failure is a correction mode.
Topically and externally applied 5 time / day. Dose and duration of treatment depend on the evidence and the dosage form.
The maximum dose: for adults with on/in the introduction – 30 mg / kg / day.
Side effect
If ingestion: nausea, vomiting, diarrhea, abdominal pain, skin rash, headache, dizziness, fatigue, poor concentration, hallucinations, drowsiness or insomnia, fever; rarely – hair loss, transient increase in blood concentrations of bilirubin, urea, creatinine, liver enzymes, Lymphocytopenia, erythropenia, leukopenia.
The on / in the introduction: acute renal failure, kristallurija, encephalopathy (confusion, hallucinations, excitation, tremor, convulsions, psychosis, drowsiness, coma), phlebitis, or inflammation at the injection, nausea, vomiting.
When applied topically: stinging at the application, superficial punctate keratitis, .Aloe, conjunctivitis.
When applied topically: at the place of application possible burning sensation, skin rash, itch, peeling, эritema, xerosis; in contact with mucous membranes – inflammation.
Contraindications
Hypersensitivity to azikloviru and valatzikloviru; at / in the introduction – lactation (breast-feeding).
Pregnancy and lactation
The use of acyclovir during pregnancy possible in cases, when the intended benefits to the mother outweighs the potential risk to the fetus.
The use of acyclovir is contraindicated in lactation (excreted in breast milk).
IN experimental studies shown in animal, What is acyclovir penetrates through the placental barrier.
Cautions
Not recommended for use in heavy human kidney function.
It should be taken into account, that when applying acyclovir may develop acute renal failure due to sedimentation of crystals of acyclovir, that is particularly likely when the rapid on/in the introduction, simultaneous use of nefrotoksicskih drugs, in patients with the human kidney and with little water load.
When applying acyclovir should monitor kidney function (determination of the level of blood urea nitrogen and creatinine in the blood plasma).
Treatment of elderly patients should be carried out with sufficient water load increases and under the supervision of a physician, tk. This category of patients increases the half-life of acyclovir.
When treating genital herpes should avoid sexual intercourse or use condoms, tk. the use of acyclovir does not prevents transmission of the virus to partners.
Acyclovir is in the form of dosage forms for the exterior should not be applied to mucous membranes of the oral cavity, eye, vagina.
Drug Interactions
Together with the use of Probenecid kanalzevu secretion reduces acyclovir and thus increases the concentration in the blood plasma and the half-life of acyclovir.
If you are applying to aziklovira with nefrotoksičeskimi drugs increases the risk of nefrotoksicski action (especially in patients with impaired renal function).
Enhancing effect of acyclovir notes while appointing immunostimulators.
When mixing solutions must take into account the alkaline reaction of acyclovir for the on/in the introduction (pH 11).
